What did @maameefua.koomson actually say?
She's switching from tirzepatide to CJC-1295, a synthetic growth hormone releasing hormone (GHRH) analog, after spraining her ankle. Her clinic suggested it, and she's now doing five injections per week, 10 units, on an empty stomach before bed. The stated goals are muscle growth, fat loss, and, after the injury, accelerated recovery. She frames the injury as almost good timing: "this is actually a perfect time to try this because it helps with like injury recovery too." That's a reasonable enough framing, but it glosses over some real gaps between what CJC-1295 does in theory and what it does in a human ankle.
She's transparent about the source, a clinic she attends in person, and she doesn't make dramatic cure claims. The video is a personal update, not medical advice. That matters when reading the rest of this.
Does the science back this up?
Partially. CJC-1295 does raise growth hormone and IGF-1 levels, and those hormones are involved in tissue repair. But the evidence for injury recovery in humans is thin, and most of what exists is animal data or small peptide-adjacent studies.
CJC-1295 is a GHRH analog that extends the half-life of growth hormone pulses. A 2006 study by Teichman et al. published in the Journal of Clinical Endocrinology and Metabolism confirmed it significantly elevates GH and IGF-1 in healthy adults over multiple doses. That part is real. Where it gets murky is the leap from "raises IGF-1" to "heals your sprained ankle faster."
IGF-1 does play a role in musculoskeletal repair. Animal studies, including work by Kasemkijwattana et al. (2000, American Journal of Sports Medicine), showed IGF-1 accelerated muscle regeneration in rat models. But a sprained ankle involves ligament and connective tissue damage, not just muscle. The connective tissue repair story for GHRH analogs specifically is largely missing from peer-reviewed literature. The claim holds mechanistic plausibility, not clinical proof.
What did they get wrong (or right)?
She got the mechanism directionally right. The comparison she makes, "if you're in the gym, you're technically like tearing your muscles and it's rebuilding," is a reasonable plain-language explanation of how anabolic signaling works. Credit where it's due.
What she understates is the difference between muscle recovery and ligament recovery. Ligaments have poor blood supply and respond differently to anabolic signals than muscle tissue does. A sprained ankle, depending on grade, may benefit more from structured physical therapy and load management than from GH stimulation. The clinic's suggestion isn't unreasonable, but framing CJC-1295 as a natural fit for ankle sprains skips over the connective tissue biology entirely.
She also doesn't mention that CJC-1295 is not FDA-approved for any of these uses. It's a compounded peptide prescribed off-label. That's a meaningful omission for a video with 10,000 views and hashtags targeting the GLP-1 community, many of whom may assume prescription equals validated use.
- Right: GH stimulation does support muscle protein synthesis and recovery broadly.
- Right: Pre-sleep, fasted timing aligns with natural GH pulse patterns.
- Incomplete: Ligament and tendon repair evidence is not the same as muscle repair evidence.
- Omitted: CJC-1295 has no FDA approval and limited human clinical trial data for recovery.
What should you actually know?
CJC-1295 is a real compound with measurable physiological effects. It is not a fringe supplement. But "measurable effects" and "proven to fix your ankle" are separated by a significant evidentiary gap that no single clinic recommendation bridges.
The dosing protocol she describes, five times per week subcutaneous injection at 10 units before bed, follows a pattern commonly used in compounding clinic protocols. The fasted, pre-sleep timing is pharmacologically sensible given that GH is naturally pulsed during slow-wave sleep. But unit-based dosing on compounded peptides can vary significantly by preparation, and listeners should not attempt to replicate this without their own clinical evaluation.
People considering peptide therapy for recovery should also know that the FDA has raised concerns about compounded peptides, including CJC-1295, in the context of oversight and purity standards. The 503B outsourcing facility framework matters here. Where a peptide is compounded affects quality controls significantly. That's worth asking your provider about directly, not assuming.
One more thing worth stating plainly: a video about recovery progress, filmed three weeks post-injury, cannot tell you whether CJC-1295 caused any improvement. Ankle sprains heal on their own. Without a control condition, the recovery she'll document is not evidence the peptide worked.
Bottom line
This is a good-faith personal health update from someone working with a clinic. It's not reckless. But the claim that CJC-1295 is "a perfect time" for ankle recovery rests on mechanism, not human outcome data for ligament injuries. Viewers should approach their own decisions with that distinction in mind.